Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Fig. 1

Schematic diagram of CD19/CD22 CAR-T structure, clinical trial enrollment, and design. A Schematic representation of the transgenes used for the two CAR-T constructs targeting CD19 and CD22. B Flow chart of patient recruitment and treatment evaluation. All patients achieved MRD-negative CR after CART2. Three patients who bridged to HSCT after CART2 were still in MRD-negative CR at the cut-off time. Of the two patients who did not receive HSCT after CART2, one died and the other was lost to follow-up. C A simplified diagram of the lymphodepletion chemotherapy conditioning regimen administered before each of the two CAR-T treatments

Back to article page